Cardio Diagnostics Holdings, Inc.
Health Care · Biotechnology
Structural: cardiovascular disease remains the #1 global killer; standard lipid/CRP panels miss ~50% of first-event MI patients, creating demand for next-gen biomarker screening. Epigenetic methylation signatures are reproducible and actionable earlier than genomic SNP panels.
PrecisionCHD fills a genuine diagnostic gap; direct-to-physician commercialization avoids hospital procurement drag; AI/epigenetics narrative could command premium multiple on any revenue inflection; tiny float magnifies any catalyst.
Pre-revenue microcap burning cash with no commercial-scale traction evidence; reimbursement pathway unclear (CPT coverage risk is binary); competing against established players (Quest, LabCorp, Foundation Medicine) with vastly more distribution; dilution risk severe at sub-$10M market cap.
No key levels recorded for this ticker.